Lymphoma accounts for 24% of all documented canine neoplasms and 85% of hematological malignancies, while multicentric lymphoma corresponds to 84% of all canine lymphomas. Canine lymphomas of B-cell origin account for 60% to 80% of lymphomas. Similar to humans, the histologic grade, architecture, as well as immunophenotype determination, are crucial. These lesions are the most prevalent spontaneous tumors in dogs and this species may be a valuable animal model for the study of human non-Hodgkin's lymphoma. Therefore, it is important to investigate and assess therapeutic responses and to seek predictive and prognostic factors in order to allow for the development of an individualized and more effective therapy that increases survival. This review aims to describe current knowledge on the diagnosis, treatment, and prognostic factors of canine multicentric lymphoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11816192 | PMC |
| http://dx.doi.org/10.3390/ani15030391 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study.
Ann Hematol
March 2025
Hematology Unit, Santa Croce E Carle Hospital, Via Michele Coppino, 26, 12100, Cuneo, Italy.
The SARS-CoV2 pandemic has posed unprecedented challenges between temporary or permanent discontinuation of immunosuppressive treatment to protect patients, or disease control prioritization by not interrupting treatment. Maintenance treatment with anti-CD20 monoclonal antibodies (MoAbs) improves progression-free survival (PFS) in follicular lymphoma (FL), but also impairs anti-SARS-CoV2 immune response. This challenge has been addressed in Italy by temporary, definitive or no discontinuation of anti-CD20 treatment.
View Article and Find Full Text PDF[Neurolymphomatosis].
Rev Med Interne
March 2025
Service de médecine interne et immunologie clinique, hôpital Bicêtre, faculté de médecine Paris Saclay, Assistance publique-Hôpitaux de Paris, université Paris Saclay, 94275 Le Kremlin-Bicêtre cedex, France; Université Paris Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases » (IMVA-HB/IDMIT/UMRS1184) Fontenay-aux-Roses, Le Kremlin-Bicêtre, France.
Neurolymphomatoses (NL) are defined as the direct infiltration of the peripheral nervous system (PNS) by lymphomatous or leukaemic cells. The diagnosis of this rare disease is complex, typically relying on peripheral nerve histology, an invasive examination with a risk of sequelae. This diagnostic entity should be considered in the presence of a painful neuropathy, sometimes severe, whether or not associated with immunohaematological abnormalities, and in cases of resistance to first-line immunomodulatory treatments.
View Article and Find Full Text PDFHaematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study.
J Eur Acad Dermatol Venereol
March 2025
Dermatology Department, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.
Background: Advanced cutaneous T-cell lymphomas (CTCL) are rare, generally refractory to therapeutic options, and have a poor prognosis. Haematopoietic stem cell transplantation (HSCT), mainly allogeneic HSCT (allo-HSCT), is considered a potentially curative option in CTCL refractory to other therapies. However, around half of patients relapse, and allo-HSCT is associated with significant adverse events.
View Article and Find Full Text PDFRisk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel.
Blood Cancer J
March 2025
Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
CAR T-cell manufacturing failure (MF) is a situation where the manufacturing process fails to yield a product or results in one which is out-of-specification (OOS). We conducted a multicentre retrospective review of factors contributing to MF and patient outcomes. Of 981 large B-cell lymphoma (LBCL) patients approved for CAR T-cell therapy, 38 (3.
View Article and Find Full Text PDFDesign, development, and evaluation of gene therapeutics specific to KSHV-associated diseases.
bioRxiv
February 2025
Department of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, USA.
Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma (KS) and two human lymphoproliferative diseases: primary effusion lymphoma and AIDS-related multicentric Castleman's disease. KSHV-encoded latency-associated nuclear antigen (LANA) is expressed in KSHV-infected cancer cells and is responsible for maintaining viral genomes in infected cells. Thus, LANA is an attractive target for therapeutic intervention for KSHV-associated diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!